Here you will find background information on the latest Merck KGaA, Darmstadt, Germany, news: features, interviews and fact sheets to help you better understand a topic.
Publication of Q3 2016 Results
“We had a good third quarter and are lifting our guidance for the full year. We have made good progress with the execution of our strategy. We have advanced our pharmaceutical pipeline and are realizing the cost synergies from the acquisition of Sigma-Aldrich faster than planned. In the course of the year, we have lowered our debt from the acquisition by € 1 billion.” Stefan Oschmann, CEO and Chairman of the Executive Board
The Access to Medicine Foundation has set itself the objective of improving access to health in low- and middle-income countries. To this end, it benchmarks the activities and initiative of the world’s 20 largest pharmaceutical companies in the Access to Medicine Index. In the recently published 2016 index, our company ranks among the top five.
By 2018, China will be the world’s second-largest pharmaceutical market. That’s why we are boosting our investments in China. In Nantong, we have inaugurated a new pharmaceutical manufacturing site to produce medicines on China’s Essential Drugs List for the treatment of diabetes, cardiovascular disease and thyroid disorders. And with the planned construction of a Life Science production facility also at the Nantong site, we want to offer products for China's pharmaceutical and biopharmaceutical industries.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.
To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone. Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
FOR MEDIA INQUIRIES, CONTACT
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Germany Tel.: +49 6151 72-5000 Fax: +49 6151 72-3138